Leveraging over ten years of expertise in the GMP manufacturing and global distribution of radiopharmaceuticals, the Centre for Probe Development and Commercialization (CPDC) launched AtomVie Global Radiopharma Inc. (AtomVie), a global leading Contract Development and Manufacturing Organization (CDMO). AtomVie empowers next-generation radiotherapeutics and thrives to support its partners from early clinical development to commercial manufacturing.

AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of your radiotherapeutics from Phase 1 to the commercial marketplace. AtomVie has in-depth experience in radiopharmaceutical manufacturing, including expertise in radiolabeling with an array of radioisotopes such as Lu-177, Ac-225, I-131 and ligands that range from small molecules, to peptides to small and large antibodies.